Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS (VaLiDate-R)
Sponsor: East and North Hertfordshire NHS Trust
This PHASE4 trial investigates Acute Coronary Syndrome and is currently ongoing. East and North Hertfordshire NHS Trust leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Recruiting PHASE4
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE4
▶ Show 2 earlier versions
-
Feb 2019 — Mar 2020 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jan 2019 — Feb 2019 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- East and North Hertfordshire NHS Trust
- University of Hertfordshire
For direct contact, visit the study record on ClinicalTrials.gov .